|

CD5/CD7 CAR-T Clinical Trials

1 actively recruiting trial

Also known as: EB-BH2026

Pipeline

Phase 1/2: 1

Top Sponsors

  • Essen Biotech1

Indications

  • T Cell Childhood ALL1
  • T-Cell Lymphoma of CNS1
  • T-cell Prolymphocytic Leukemia1
  • T-cell Leukemia1
  • T - Cell Lymphoma1

Other1 trial

Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.